103 related articles for article (PubMed ID: 2399525)
1. [Toxic myopathy due to hypolipemic agents].
Bourrier P; Subra JF; Chennebault JM; Spiesser R; Laine P
Therapie; 1990; 45(4):360. PubMed ID: 2399525
[No Abstract] [Full Text] [Related]
2. Bezafibrate does not influence the QT interval in man.
Olsson AG; Ekelund LG; Lang PD; Vollmar J
J Cardiovasc Pharmacol; 1983; 5(2):341-2. PubMed ID: 6188913
[No Abstract] [Full Text] [Related]
3. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
Baglin A; Lasserre N; Prinseau J; Lebas M
Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
[No Abstract] [Full Text] [Related]
4. [Hypolipemic effect of amino acid derivatives of clofibric acid].
Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
[No Abstract] [Full Text] [Related]
5. [Plafibride--is it an effective drug as a hypolipemic agent?].
Joven J
Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
[No Abstract] [Full Text] [Related]
6. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
[No Abstract] [Full Text] [Related]
7. [Rhabdomyolysis with acute renal failure due to bezafibrate].
Heidemann H; Bock KD
Klin Wochenschr; 1981 Apr; 59(8):413-4. PubMed ID: 7289450
[No Abstract] [Full Text] [Related]
8. [Plafibride treatment of hyperlipidemias type II and IV].
Soler J; Vinzia C; Gómez JM; Morató J
Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
[No Abstract] [Full Text] [Related]
9. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
10. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Słowińska R; Bochenek W; Unlot J
Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
[No Abstract] [Full Text] [Related]
11. Hypolipemic activity of plafibride.
Bruseghini L; Vilageliu J; Bagaria A
Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of vascular insufficiency of the legs with plafibride].
Lázaro Campillo T; Gesto Castromil R; de la Sierra L; Pujadas J; Villafana W; Moreno R
Med Clin (Barc); 1984 Dec; 83(18):752-5. PubMed ID: 6521538
[No Abstract] [Full Text] [Related]
13. [Therapeutic effects of bezafibrate in hyperlipidemia].
Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
[No Abstract] [Full Text] [Related]
14. [Therapy of ischemic ulcers of the lower extremities using plafibride].
Palou Monzo J; López-Delmás FJ
Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
[No Abstract] [Full Text] [Related]
15. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
Schatton W; Holm E
Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
[No Abstract] [Full Text] [Related]
16. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacology and mechanism of action of etofibrate].
Schatton W
Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
[No Abstract] [Full Text] [Related]
18. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.
Bardosi A; Scheidt P; Goebel HH
Acta Neuropathol; 1985; 68(2):164-8. PubMed ID: 4072624
[TBL] [Abstract][Full Text] [Related]
20. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
[No Abstract] [Full Text] [Related]
[Next] [New Search]
